FDA Authorizes First-of-Its-Kind Robotic Blood Draw Device, Aletta
核心洞察
The FDA authorized Vitestro (搜索)'s Aletta (搜索), the first standalone robotic device that draws blood from a patient's arm without hands-on operator intervention.
Aletta (搜索) uses near-infrared light, Doppler ultrasound, robotics, and AI to locate veins, insert the needle, and complete the blood draw autonomously.
One phlebotomist can oversee up to three Aletta (搜索) devices, which may help address the growing shortage of trained phlebotomists in the U.S.
The U.S. Food and Drug Administration has authorized Aletta (搜索), the first standalone robotic device capable of drawing blood from a patient's arm without hands-on operator intervention. Developed by Vitestro (搜索), the device received marketing authorization through the FDA's De Novo pathway, a regulatory route for low- to moderate-risk devices of a new type. The authorization, announced from Silver Spring, Maryland, is intended for use in adults in outpatient settings and must be operated under the oversight of a supervisor trained in phlebotomy.
"This authorization reflects the FDA's commitment to advancing innovative medical devices that help meet a critical public health need while maintaining the safety and effectiveness patients deserve," said Michelle Tarver, M.D., Ph.D., Director of the FDA's Center for Devices and Radiological Health. "Blood draws are one of the most commonly performed medical procedures in the United States, yet patients may face delays due to a growing shortage of trained phlebotomists."
How Aletta Works
Using imaging, robotics, and artificial intelligence, Aletta (搜索) finds veins, guides needle insertion, and collects blood samples. The device employs multiple forms of ultrasound—including near-infrared light and Doppler ultrasound—to locate a suitable vein and differentiate it from arteries. If no appropriate vein is found, the device will not attempt the procedure.
Aletta (搜索) handles each step of the process autonomously, from applying a tourniquet to covering the needle puncture site with a bandage. Specifically, once a vein is identified, the device proceeds through the remaining steps on its own: applying a tourniquet, preparing the skin, inserting and disposing of the needle, changing collection tubes, and placing a bandage. The supervising phlebotomist's role is limited to confirming that collection tubes are filled in the correct order, verifying that all tubes are adequately full following the procedure, and responding to alerts issued by the device.
Patient Safety Features
Aletta (搜索) is designed with multiple layers of patient safety in mind. The device continuously applies disinfectant to the skin during the ultrasound scan, and a trained professional must clean Aletta between patients. If a patient moves too much during the procedure, the needle automatically detaches and the draw stops; additional onboard sensors can pause the procedure and alert the supervisor if other unsafe conditions are detected.
Addressing the Phlebotomist Shortage
One phlebotomist can oversee up to three Aletta (搜索) devices at the same time, leading the FDA to predict that Aletta may help address the shortage of people trained to take blood samples in the U.S. The device guides the patient to position their arm, after which the patient or supervisor presses a button to start the blood draw.
Clinical Evidence and Regulatory Framework
The FDA's authorization is based on clinical data demonstrating that Aletta (搜索) achieves successful blood draw rates comparable to or better than trained human phlebotomists when it proceeds with a stick. This was demonstrated across a broad range of patients, including those with varying health statuses, those who self-reported having difficult vein access, and those with varying skin tones. Device-related adverse events were uncommon and mild.
Along with the De Novo authorization, the FDA is establishing special controls that define requirements related to labeling, performance testing, and clinical testing. When met, these special controls, in combination with general controls, provide a reasonable assurance of safety and effectiveness, and support the development of other robotic blood draw devices via the 510(k) pathway.
Commercial Trajectory
Vitestro (搜索) raised $70 million in March to bring the device to the U.S. market. The venture capital wing of Labcorp (搜索), which employs phlebotomists to take blood samples for testing at its laboratories, participated in the financing round, as did Mayo Clinic, Sutter Health, and Intuitive co-founder Fred Moll. Aletta (搜索) received a CE mark in 2024, allowing Vitestro to start an initially limited market release in Europe. The company's planned uses for the funding included manufacturing scale-up, clinical expansion, and commercial infrastructure development, with broader market adoption beginning in Europe and progressing toward the U.S. market.